Blog

Singapore’s Tessa raises $80M for T cell therapy push – FierceBiotech


FierceBiotech

Singapore's Tessa raises $80M for T cell therapy push
FierceBiotech
The VST approach has some similarities with autologous CART therapies, and involves harvesting white blood cells from peripheral blood, stimulating them to proliferate and respond to tumor cells expressing viral antigens, and then infusing the cells
Parker Institute-allied Tessa grabs an $80M round for its next-gen cancer cell therapiesEndpoints News



all 5 news articles »

2017-12-20 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.